XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3
Organization and Basis of Presentation (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Jun. 02, 2023
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Aug. 19, 2024
Jun. 30, 2024
Dec. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Apr. 09, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Minimum net stockholders equity maintaining in nasdaq $ 2,500,000                    
Stock holders' equity   $ (1,366,936) $ (4,922,960) $ (1,366,936) $ (4,922,960)   $ (2,246,139) $ (3,994,762) $ (2,692,534) $ (5,165,227)  
Net loss   986,030 1,018,760 2,968,271 4,054,774            
Net cash used in operations       2,565,861 3,391,142            
Cash   1,637,627   1,637,627       4,203,488     $ 40,000
Clinical Trial Agreements And Clinical Trial Monitoring Agreements [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Contractual Obligation   3,918,000   3,918,000              
Minimum [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Stock holders' equity           $ 2,500,000          
Common Stock [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Reverse stock split 1-for-10                    
Stock holders' equity   (225) (225) (225) (225)   $ (225) $ (225) $ (166) $ (166)  
Net loss              
Common Stock [Member] | Minimum [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Bid price $ 1.00